Key Services
We are committed to launching products that make a difference in people’s lives. We work across a product’s lifecycle, supporting biotech, pharmaceutical, and medical technology companies across the globe.
Outcomes Research
Our team provide unequalled accuracy and quality whilst delivering all aspects of systematic reviews, meta-analyses and patient-level data analyses.
Economic Modelling
We develop a range of robust health economic models that meet the commercial needs of our clients from simple Markov models to complex discrete event simulations.
Health Technology Assessment
We have extensive experience delivering successful HTA submissions in the UK and across the globe.
Value Communication
We effectively communicate the value of your products in a logical and insightful manner; from internal value dossiers to external scientific publications.
Pricing & Reimbursement
We partner with our clients to develop strategies for global pricing and reimbursement, harnessing our extensive KOL and payer network.
“FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”
Senior Market Access Manager, Mid-sized Pharma
“FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”
Disease Area Director, Big Pharma
“It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”
Associate Director, Mid-sized Pharma
“FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”
Market Access Director, Small Biotech
“FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”
Value Demonstration & Access Lead, Big Pharma
“It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”
Senior Vice President, Small Biotech
ICER FRAMEWORK
The Institute for Clinical and Economic Review (ICER) published an updated Value Assessment Framework document on 31st January outlining the principles, methodology, and deliberation procedures that will guide future ICER assessments.
These updates are based on ICER’s ongoing efforts to learn from patient groups and others about how to build a unique approach to value assessment that can reflect core principles of respect for all participants, transparency of methods and decision-making rationales, inclusive of all perspectives, and objectivity grounded in rigorous evaluation of all relevant evidence.
Source: ICER press release 31.01.2020
TOP 10 HEOR TRENDS
ISPOR COPENHAGEN
Thank you to everyone who came to visit us at ISPOR, it was a pleasure to catch up and meet with so many people. We presented three posters and the launch of our new product, FIECON Value Platform was a rip roaring success too! Please contact our Managing Director, Mark Fisher - mark.fisher@fiecon.com if you would like to arrange a FIECON Model Builder demo, FIECON Value Platform demo or to hear about our services and how FIECON can support your projects.
FIECON VALUE PLATFORM LAUNCH
FIECON Value Platform can help you manage and optimise your product’s pricing and market access processes. Your online portal helps Global teams quickly understand progress, priorities, and support needs in local markets, saving you time, increasing team efficiency, and ensuring unity and alignment. Save time, increase efficiency and ensure unity and alignment to give your products the best chance of achieving successful pricing and market access.
Get in touch with our Pricing and Market Access Director, Mike Blackney - mike.blackney@fiecon.com, to book a demo or find out more.
MODELS IN MINUTES
FIECON Model Builder is an online platform which automates the design and building-process of Excel-based cost-effectiveness models. High quality Excel models can be built in a matter of minutes rather than weeks. Models are set up with complete functionality, flexibility, and transparency. But most importantly our automated process removes the risk of human error and guarantees accuracy. Give yourself the best chance of success; save time and money with the right cost-effectiveness model from FIECON Model Builder.
Get in touch with our Strategy Director, Lewis Ruff - lewis.ruff@fiecon.com, to book a demo or find out more.
AWARD WINNER 2019
Team FIECON were thrilled to win the Business Growth award at the St Albans Chamber of Commerce, Community Business awards.
NICE METHOD REVIEW
Mark Fisher, our Managing Director, participated and gave evidence in the Access to Medicines and Medical Devices All-Party Parliamentary Group (APPG) NICE Methods Review inquiry at the House of Commons in May. The APPG report has now been published which provides clear recommendations and suggestions for crucial areas for future research and work outside of the NICE review.
Contact mark.fisher@fiecon.com for more information about how this may impact your products, and how FIECON can help you navigate the best path for you going forward.
HOSTED AT HOUSE OF COMMONS
Mark Fisher, our Managing Director, was speaking at the House of Commons alongside Sir Andrew Dillon (NICE), Helen Knight (NICE), and Karl Claxton (University of York) as part of the APPG inquiry into the NICE STA and HST methods. For full notes please email mark.fisher@fiecon.com - key topics of discussion surrounded how NICE processes can look to close the gap between appraisals for rare and ultra-rare medicines, the role of NICE and NHS England in the assessment of budget impact, whether wider societal costs should be considered for the future, and much more.